Novavax (NVAX) stock price, revenue, and financials

Novavax market cap is $15.5 b, and annual revenue was $475.6 m in FY 2020

$15.5 B

NVAX Mkt cap, 11-Jun-2021

$447.2 M

Novavax Revenue Q1, 2021
Novavax Net income (Q1, 2021)-222.7 M
Novavax EBIT (Q1, 2021)-208.6 M
Novavax Cash, 31-Mar-20212 B
Novavax EV13.9 B

Novavax Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

3.0m5.0m4.6m7.1m5.8m3.8m3.5m4.8m7.5m8.3m8.2m9.9m14.0m6.5m4.2m2.5m3.2m5.7m6.7m8.4m9.7m10.8m7.7m4.0m3.4m2.5m3.4m35.5m447.2m

Cost of goods sold

3.8m5.1m3.8m1.7m1.6m2.3m3.0m5.1m2.5m2.7m2.7m

Gross profit

856.0k2.0m1.9m2.1m1.9m2.5m4.4m3.2m7.4m11.3m3.8m

Gross profit Margin, %

18%28%33%55%54%53%60%38%75%81%58%

R&D expense

5.6m6.2m5.1m5.2m6.4m9.4m10.8m13.9m14.5m15.2m19.2m25.9m25.0m27.9m69.0m64.9m53.0m37.7m39.3m41.9m44.5m44.5m41.3m35.5m30.4m18.6m16.9m34.8m592.7m

General and administrative expense

3.3m2.7m3.2m2.7m2.4m2.7m4.0m3.9m4.3m5.8m4.8m5.8m7.1m9.1m10.5m14.1m13.6m8.9m8.9m8.1m8.7m8.2m8.3m8.7m9.6m7.9m9.4m17.7m63.2m

Operating expense total

8.9m9.0m8.3m7.8m8.8m12.1m14.8m17.8m18.8m21.0m28.0m31.7m32.1m37.0m79.5m79.0m66.5m46.5m48.2m50.0m53.2m52.8m49.6m44.2m40.0m26.5m26.3m52.6m655.9m

EBIT

(5.9m)(4.0m)(7.5m)(5.9m)(6.8m)(10.0m)(12.9m)(15.3m)(14.4m)(17.9m)(19.8m)(24.3m)(20.8m)(33.2m)(75.3m)(76.5m)(63.3m)(40.8m)(41.5m)(41.6m)(43.5m)(42.0m)(41.9m)(40.2m)(36.7m)(15.0m)(22.9m)(17.0m)(208.6m)

EBIT margin, %

(197%)(79%)(161%)(82%)(119%)(261%)(365%)(318%)(193%)(216%)(241%)(246%)(149%)(509%)(1784%)(3054%)(1959%)(719%)(616%)(498%)(451%)(390%)(542%)(1010%)(1092%)(598%)(678%)(48%)(47%)

Interest expense

2.0k2.0k3.0k3.0k6.0k22.0k45.0k47.0k

Interest income

18.0k128.0k

Investment income

38.0k22.0k33.0k39.0k39.0k48.0k48.0k53.0k12.0k20.0k121.0k134.0k194.0k473.0k670.0k554.0k474.0k523.0k531.0k531.0k807.0k752.0k420.0k474.0k342.0k436.0k297.0k362.0k

Pre tax profit

(4.6m)(3.2m)(5.9m)(7.2m)(10.0m)(12.6m)(15.3m)(13.8m)(17.9m)

Income tax expense

412.0k17.0k5.0k3.0m

Net Income

(5.0m)(3.2m)(7.3m)(5.9m)(7.2m)(10.0m)(12.6m)(15.3m)(13.8m)(17.9m)(19.7m)(24.4m)(20.6m)(33.1m)(77.3m)(79.4m)(66.3m)(43.9m)(44.5m)(44.6m)(46.4m)(44.5m)(44.6m)(43.2m)(39.6m)(18.0m)(25.9m)(17.5m)(222.7m)

Novavax Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

14.1m17.4m119.5m32.3m93.1m144.4m106.3m70.2m78.8m553.4m

Accounts Receivable

2.0m1.0m1.9m7.5m2.3m233.0k7.5m262.0m

Prepaid Expenses

2.4m2.6m17.8m16.3m8.0m181.3m

Inventories

9.2m19.3m21.8m

Current Assets

26.1m50.4m145.0m188.2m287.3m287.8m203.3m119.3m97.2m1.2b

PP&E

6.9m11.5m14.3m19.7m32.3m40.2m36.0m28.4m11.4m180.0m

Goodwill

33.1m33.1m59.5m54.6m53.1m51.7m53.6m52.0m51.2m135.4m

Total Assets

66.6m102.3m235.9m276.0m386.0m394.3m302.5m208.0m173.0m1.6b

Accounts Payable

2.6m3.2m6.0m12.9m11.9m5.7m5.6m9.3m2.9m54.3m

Short-term debt

20.0k(157.0k)5.1m8.9m

Current Liabilities

7.6m11.7m18.9m34.1m76.5m66.4m73.7m45.5m25.8m579.7m

Long-term debt

300.0k237.0k320.6m362.1m

Total Debt

320.0k80.0k317.8m319.2m325.7m371.0m

Total Liabilities

12.7m22.1m399.8m404.2m375.9m359.0m955.3m

Common Stock

1.2m1.5m3.2m3.8m324.0k714.0k

Preferred Stock

Additional Paid-in Capital

383.9m438.9m612.9m729.4m951.6m936.0m1.0b1.1b1.3b2.5b

Retained Earnings

(329.7m)(358.2m)(410.1m)(493.1m)(650.0m)(930.0m)(1.1b)(1.3b)(1.4b)(1.9b)

Total Equity

53.8m80.2m203.2m229.6m292.7m(5.5m)(101.7m)(167.9m)(186.0m)627.2m

Debt to Equity Ratio

-3.1 x-1.9 x

Debt to Assets Ratio

1.1 x1.5 x

Financial Leverage

1.2 x1.3 x1.2 x1.2 x1.3 x-71.1 x-3 x-1.2 x-0.9 x2.5 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

13.1m14.3m13.9m15.3m10.7m9.0m2.6m122.5m109.9m103.9m34.5m215.1m167.4m138.1m132.2m89.4m119.9m95.8m75.8m104.2m113.4m88.5m56.5m97.7m72.0m71.2m179.9m424.4m2.0b

Accounts Receivable

1.8m17.0k1.7m1.5m2.5m2.6m907.0k1.9m4.5m3.7m6.7m2.3m2.2m406.0k363.0k591.0k56.9m

Prepaid Expenses

2.2m2.4m2.4m2.5m2.8m2.2m2.0m3.0m4.6m5.1m11.5m13.2m15.6m20.7m19.9m21.5m20.0m19.2m21.0m17.7m17.1m15.8m16.6m11.6m13.5m11.0m27.3m114.7m

Current Assets

28.4m26.3m26.4m35.0m36.5m51.7m45.4m155.0m128.9m166.6m192.0m350.1m333.0m310.1m484.6m420.0m353.9m258.4m236.7m226.0m181.0m194.3m160.5m123.4m110.2m89.0m255.2m636.4m2.2b

PP&E

7.6m7.5m7.9m7.8m9.8m11.6m13.3m14.0m14.3m15.1m17.5m24.0m26.1m29.4m36.6m39.7m41.0m39.4m38.5m37.3m32.4m30.8m29.3m27.0m13.0m12.2m10.8m115.4m192.0m

Goodwill

33.1m33.1m33.1m33.1m33.1m33.1m33.1m58.8m58.6m57.9m56.2m52.7m53.3m53.1m53.8m52.9m52.7m51.9m53.0m53.7m53.3m52.0m52.1m51.2m51.3m50.3m50.0m118.8m130.9m

Total Assets

69.3m67.1m68.6m77.0m80.5m98.7m92.9m245.1m218.6m312.0m292.5m438.8m424.7m404.6m592.5m525.0m459.6m361.5m355.7m334.1m276.1m285.8m250.5m221.3m189.4m164.8m328.1m932.2m2.6b

Accounts Payable

3.0m2.4m3.0m3.4m2.2m2.2m2.9m3.3m4.0m4.5m3.0m9.7m7.1m8.2m11.2m16.0m16.2m3.8m8.0m5.2m5.8m6.7m6.8m6.2m4.3m4.2m2.5m9.2m113.6m

Short-term debt

60.0k40.0k7.0k57.0k59.0k60.0k115.0k105.0k97.0k579.0k532.0k493.0k252.0k149.0k45.0k2.0m5.1m

Current Liabilities

9.0m6.7m7.8m9.4m10.4m9.3m11.3m14.3m13.7m17.5m18.6m28.8m27.1m24.9m71.1m81.9m75.7m56.5m66.8m68.3m44.9m43.0m46.7m31.5m41.5m21.6m19.0m213.3m1.2b

Long-term debt

300.0k300.0k400.0k400.0k252.0k222.0k206.0k222.0k191.0k172.0k252.0k149.0k45.0k321.0m321.3m339.1m

Total Debt

360.0k340.0k407.0k400.0k309.0k281.0k266.0k337.0k296.0k269.0k831.0k681.0k538.0k504.0k298.0k90.0k316.7m317.1m317.4m318.1m318.5m318.8m319.5m319.9m320.3m323.0m326.4m339.1m

Total Liabilities

13.1m12.5m14.3m15.9m19.2m21.1m23.7m28.5m27.5m30.3m30.9m39.1m37.1m37.6m407.1m414.9m409.8m390.6m414.8m408.2m375.4m373.5m377.2m371.9m374.9m354.6m352.0m547.9m1.6b

Common Stock

1.2m1.2m1.2m1.3m1.4m1.5m1.5m2.1m2.1m2.4m2.7m2.7m2.7m2.7m2.7m2.7m2.8m2.9m3.1m3.5m3.8m3.8m4.7m235.0k256.0k539.0k612.0k745.0k

Preferred Stock

199.8m

Additional Paid-in Capital

381.0m380.9m391.6m404.2m411.6m446.2m450.3m611.9m615.3m724.9m727.4m926.7m934.2m947.1m920.0m925.6m932.2m956.3m969.0m997.0m1.1b1.1b1.1b1.2b1.2b1.2b1.5b1.7b3.2b

Retained Earnings

(322.7m)(326.0m)(337.0m)(342.9m)(350.1m)(368.2m)(380.8m)(396.1m)(424.0m)(441.8m)(461.5m)(517.5m)(538.1m)(571.2m)(727.3m)(806.6m)(872.9m)(974.4m)(1.0b)(1.1b)(1.2b)(1.2b)(1.2b)(1.3b)(1.4b)(1.4b)(1.5b)(1.5b)(2.1b)

Total Equity

56.3m54.6m54.3m61.1m61.4m77.6m69.2m216.6m191.1m281.7m261.7m399.7m387.6m367.0m185.4m110.1m49.8m(29.1m)(59.1m)(74.2m)(99.4m)(87.7m)(126.7m)(150.6m)(185.5m)(189.8m)(24.0m)184.5m1.0b

Debt to Equity Ratio

0 x0 x0 x-10.9 x-5.4 x-4.3 x-3.2 x-3.6 x-2.5 x-2.1 x-1.7 x-1.7 x

Debt to Assets Ratio

0 x0 x0 x0.9 x0.9 x1 x1.2 x1.1 x1.3 x1.4 x1.7 x1.9 x

Financial Leverage

1.2 x1.2 x1.3 x1.3 x1.3 x1.3 x1.3 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x3.2 x4.8 x9.2 x-12.4 x-6 x-4.5 x-2.8 x-3.3 x-2 x-1.5 x-1 x-0.9 x-13.7 x5.1 x2.5 x

Novavax Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(19.4m)(28.5m)(52.0m)(82.9m)(156.9m)(280.0m)(183.8m)(184.7m)(132.7m)(418.3m)

Depreciation and Amortization

1.6m1.7m2.6m4.4m6.0m8.5m9.8m8.2m5.7m4.9m

Accounts Receivable

(1.9m)954.0k2.1m245.9m

Accounts Payable

(2.7m)2.0m4.2m14.0m9.1m(4.8m)5.2m(6.7m)(11.5m)163.2m

Cash From Operating Activities

(23.6m)(18.2m)(45.4m)(87.1m)60.8m(255.5m)(138.7m)(184.8m)(136.6m)(42.5m)

Purchases of PP&E

(610.0k)(4.3m)(4.2m)(1.4m)(1.9m)(54.6m)

Capital Expenditures

(5.8m)(7.3m)(18.3m)(18.2m)

Cash From Investing Activities

18.5m(32.3m)16.4m(129.8m)(21.3m)28.0m36.0m28.6m38.5m(377.8m)

Short-term Borrowings

(473.0k)(671.0k)(395.0k)(600.0k)

Long-term Borrowings

(104.0k)(37.0k)(96.1m)

Cash From Financing Activities

11.1m53.8m131.0m109.7m208.3m279.0m64.5m102.8m98.4m984.8m

Net Change in Cash

6.0m3.3m(38.0m)(53.5m)221.0k566.6m

Interest Paid

20.0k12.2m12.2m12.2m13.7m

Free Cash Flow

(51.1m)(94.4m)42.5m(273.7m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(12.4m)(15.7m)(7.3m)(13.3m)(20.5m)(10.0m)(22.6m)(37.9m)(13.8m)(31.7m)(51.4m)(24.4m)(45.0m)(78.1m)(77.3m)(156.6m)(222.9m)(43.9m)(88.3m)(132.9m)(46.4m)(90.8m)(135.4m)(43.2m)(82.8m)(100.9m)(25.9m)(43.4m)(222.7m)

Depreciation and Amortization

788.0k1.2m404.0k810.0k1.2m449.0k961.0k1.6m980.0k2.0m3.0m1.3m2.8m4.3m2.0m4.1m6.3m2.1m4.2m7.7m2.1m4.1m6.2m1.9m3.9m4.7m925.0k1.9m

Accounts Receivable

(1.8m)37.0k240.0k467.0k(504.0k)(1.6m)104.0k(291.0k)(2.6m)(1.8m)(999.0k)1.0m5.4m5.5m1.9m2.0m1.7m

Accounts Payable

(3.8m)(3.7m)40.0k1.6m(304.0k)(1.6m)(40.0k)623.0k(4.0m)(1.3m)(164.0k)(7.6m)(8.3m)(7.7m)1.5m9.0m6.4m(4.9m)(105.0k)364.0k(13.3m)(6.5m)(10.5m)(11.9m)(11.0m)(16.9m)(8.4m)27.1m53.3m

Cash From Operating Activities

(17.4m)(20.8m)(4.2m)(10.3m)(14.1m)(10.6m)(18.2m)(33.1m)(20.4m)(31.4m)(47.2m)(30.5m)(42.8m)(71.3m)(69.8m)(131.9m)(194.2m)(38.6m)(69.4m)(106.6m)(66.1m)(106.0m)(139.6m)(50.6m)(80.6m)(112.9m)(23.1m)92.5m663.1m

Purchases of PP&E

(178.0k)(414.0k)(772.0k)(1.1m)(2.2m)(1.5m)(3.2m)(4.8m)(889.0k)(1.8m)(4.9m)(4.9m)(9.2m)(13.6m)(5.5m)(11.0m)(15.0m)(1.1m)(2.3m)(3.5m)(150.0k)(459.0k)(855.0k)(805.0k)(1.3m)(1.6m)(122.0k)(3.9m)(13.8m)

Cash From Investing Activities

14.1m17.7m(3.3m)(7.8m)(15.1m)(5.0m)(8.2m)7.2m9.7m(93.1m)(147.2m)17.8m(21.6m)(30.8m)(169.4m)(150.5m)(57.9m)(25.3m)(22.8m)19.2m20.6m(27.7m)(19.7m)18.7m20.7m38.7m(57.7m)(245.9m)141.6m

Long-term Borrowings

(90.0k)(14.0k)(29.0k)(54.0k)(6.0k)(32.0k)(58.0k)(16.0k)(33.0k)(49.0k)(19.0k)(37.0k)(53.0k)(18.0k)(37.0k)(37.0k)(12.0m)

Cash From Financing Activities

8.4m9.3m7.3m19.4m25.9m7.2m11.6m130.9m1.2m108.9m109.4m195.5m199.6m208.1m278.4m278.6m279.1m15.4m23.5m47.1m43.9m97.9m98.9m56.2m56.2m68.2m185.9m602.5m577.0m

Net Change in Cash

5.0m6.3m(231.0k)1.2m(3.4m)(8.4m)(14.8m)105.1m(9.5m)(15.6m)(85.0m)182.7m135.0m105.8m39.1m(3.7m)26.8m(48.5m)(68.6m)(40.1m)(1.6m)(35.9m)(60.4m)24.2m(3.7m)(6.0m)105.0m449.4m1.4b

Interest Paid

20.0k61.0k120.0k52.0k100.0k143.0k31.0k57.0k79.0k12.0k21.0k6.2m6.1m6.1m12.2m6.1m6.1m12.2m6.1m6.1m12.2m6.1m6.1m7.5m

Income Taxes Paid

3.0m

Novavax Ratios

USDQ2, 2011

Financial Leverage

1.2 x

Novavax Operating Metrics

FY, 2016

Patents (US)

250

Phase I Trials Products

2

Phase II Trials Products

1

Phase III Trials Products

1

Pre-Clinical Phase Products

3

Novavax Employee Rating

3.6106 votes
Culture & Values
3.8
Work/Life Balance
3.5
Senior Management
3.2
Salary & Benefits
4
Career Opportunities
3.4
Source